KYBELLA

Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center







Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center

Consumers Are Concerned About Their Submental Fullness

Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center

Key Anatomic Landmarks of the Cervicomental Region



Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center

KYBELLA™ (deoxycholic acid) Injection Contours Submental Fullness Through Destruction of Fat Cells

When injected into subcutaneous fat, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.



To avoid potential tissue damage, KYBELLA™ should not be injected into or in close proximity to vulnerable anatom structures.

Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center

kybella™

28 Days



Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center



Pre-Treatment



Post-Treatment

Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center

KYBELLA
Double Chin (Submental Fullness)



Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center

The Safety Profile of KYBELLA™ (deoxycholic acid) Injection Is Well-Characterized

Most Common Adverse Reactions Were Primarily Associated With the Treatment Area*

ADVERSE REACTIONS	KYBELLA™ (N=513) n (%)	PLACEBO (N=506) n (%)
Injection site reactions	492 (96%)	411 (81%)
edema/swelling	448 (87%)	218 (43%)
hematoma/bruising	368 (72%)	353 (70%)
pain	356 (70%)	160 (32%)
numbness	341 (66%)	29 (6%)
erythema	136 (27%)	91 (18%)
induration	120 (23%)	13 (3%)

*Adverse reactions that occurred in >20% KYBELLA™ treated subjects and at greater incidence than placebo

Adverse reactions that occurred in <20% of KYBELLA™-treated subjects included paresthesia, nodule, pruritus, skin tightness, site warmth, nerve injury, headache, oropharyngeal pain, hypertension, nausea, and dysphagia.

Other adverse reactions associated with the use of KYBELLA include: injection site hemorrhage, injection site discoloration, pre-syncope/syncope, lymphadenopathy, injection site urticaria, and neck pain.

kybella™ (deoxycholic acid) injection

KYBELLA™ Prescribing Information. KYTHERA Biopharmaceuticals, Inc. 2015.

Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center

SELECT Dose
Determine KYBELLA™ (deoxycholic acid) Injection Dose

S

Determine number of 1 mL syringes needed

- Count the number of dots in the treatment area and divide by 5
- Ignore any dots that fall outside of the pre-marked treatment area



kybella (deoxycholic acid) injection

KYBELLA™ Prescribing Information. KYTHERA Biopharmaceuticals, Inc. 2015.

85

SELECT KYBELLA™ (deoxycholic acid) Injection Dose
Count the Number of Dots in the Pre-Defined Treatment Area

S

Number of Dots	Total Dose (mL)* = Number of 1-mL Syringes	Number of KYBELLA™ Vials
5	1	0.5
10	2	1
15	3	1.5
20	4	2
25	5	2.5
30	6	3
35	7	3.5
40	8	4
45	9	4.5
50	10*	5

*In clinical trials, the average total dose was 4 to 6 mL, or between 2 to 3 vials, of KYBELLA™ administered in a single treatment session. No more than 10 mL, or 5 vials, of KYBELLA™ per treatment session is recommended.

Discard unused portions of KYBELLA™ vials.

kybella (deoxycholic acid) injection

86

Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center



Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center
Kythera Study Patient



Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center
Kythera Study Patient



Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center
Kythera Study Patient



Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center
Kythera Study Patient



Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center
Kythera Study Patient



Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center
Kythera Study Patient



Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center
Kythera Study Patient



Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center
Kythera Study Patient

KYBELLA™ THE FIRST AND ONLY FDA APPROVED INJECTABLE DRUG THAT CONTOURS AND IMPROVES THE APPEARANCE OF SUBMENTAL FULLNESS

- CLINICAL PROGRAM
- TOPLINE RESULTS
- DOSING
- PATIENT SATISFACTION

79%

of patients treated with KYBELLA™ reported satisfaction with their appearance in association with their face and chin*

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/ bruising, pain, numbness, erythema, and induration.

*In response to the question, "Considering your appearance in association with your face and chin, how satisfied do you feel with your appearance at the present time whether or not in your judgment it is due entirely to treatment with KYBELLA™?"

kybella™
(deoxycholic acid) injection

Drugs@FDA. FDA Approved Drug Products. Available at: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetail Accessed May 21, 2015.
KYBELLA™ Prescribing Information. KYTHERA Biopharmaceuticals, Inc. 2015.
Data on file, KYTHERA Biopharmaceuticals, Inc.

Roger A. Dailey, MD, FACS
Casey Aesthetic Facial Surgery Center